

---

## **NOTICE TO SHAREHOLDERS OF ADOPTION OF FINANCIAL REPORTING STANDARD (“FRS”) 102 – ‘REDUCED DISCLOSURE FRAMEWORK’ FOR PARENT ENTITY**

**DATE: March 11, 2016**

London (United Kingdom) - Following the publication of FRS 100 ‘Application of financial reporting requirements’, by the financial reporting council, Stallergenes Greer plc (the “Company”) (Euronext Paris: STAGR), a biopharmaceutical company specializing in treatments for respiratory allergies, is required to change its accounting framework for its entity financial statements, which is currently UK GAAP, for its financial year commencing 1 January 2015.

After due consideration, Stallergenes Greer plc plans to adopt FRS102 ‘Reduced disclosure framework’.

Please note the ‘reduced disclosure framework’ applies to the parent company financial statements only. The consolidated group financial statements will be published in accordance with international financial reporting standards (IFRS), as published by the International Accounting Standards Board (IASB) and adopted by the European Union.

A shareholder or shareholders holding in aggregate 5% or more of the total allotted shares in Stallergenes Greer plc can serve objections to the use of the disclosure exemptions, in writing, to its registered office address (1 Curzon Street, London, W1J 5HD, UK) no later than 25 March 2016.

### **ABOUT STALLERGENES GREER PLC**

Headquartered in London (UK), Stallergenes Greer plc is a global healthcare company specializing in the diagnosis and treatment of allergies through the development and commercialization of allergy immunotherapy products and services. Stallergenes Greer plc is the parent company of GREER Laboratories, Inc. (whose registered office is in the U.S.) and Stallergenes S.A.S. (whose registered office is in France).

#### **Trading information:**

Name: Stallergenes Greer

ISIN: GB00BZ21RF93 1 - Ticker: STAGR

ICB classification 4577

Market: Euronext Paris regulated market

Additional information is available at <http://www.stallergenesgreer.com>

*This document (including information incorporated by reference in this document), oral statements made and other information published by the company contain statements that are or may be forward-looking with respect to the financial condition and/or results of operations and businesses of the Company. These statements can be identified by the use of forward-looking terminology such as "believe", "expects", "project", "estimated", "forecast", "should", "plan", "may" or the negative of any of these, or other variations thereof, or comparable terminology indicating expectations or beliefs concerning future events. These forward-looking statements include risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. Without being exhaustive, such factors include economic situations and business conditions, including legal and product evaluation issues, fluctuations in currencies and demand, and changes in competitive factors. These and other factors are more fully described in our prospectus filed with the French Autorité des marchés financiers on September 3, 2015. Actual results may differ from those set forth in the forward-looking statements, due to various factors. Save as required by applicable law, neither the Company nor any other person assumes any obligation to update these forward-looking statements or to notify any person of any such update.*

**Contacts:**

**Investor and analyst relations**

Peter Bühler  
 Chief Financial Officer  
 Tel: +33 1 55 59 23 22  
 Email: investorrelations@aresallergyco.com

**Media relations**

Lise Lemonnier  
 Head of Global Communications  
 Tel: + 33 1 55 59 20 96  
 Email: llemonnier@stallergenes.com

**Investor relations agency**

FTI Consulting  
 Arnaud de Cheffontaines  
 Tel: +33 1 47 03 69 48  
 Email:  
 arnaud.decheffontaines@fticonsulting.com